Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Tianjin
Clinical trial register · China

Clinical Trials in Tianjin, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19224 matching records held by the registry are in this view. Synced 11 Nov 2026, 03:17 UTC
19224
Studies in scope
all four open statuses
11811
Recruiting now
open to new participants
2030
Lead sponsors
across recruiting studies
Top sites
Beijing 5586 Shanghai 3885 Guangzhou 3356 Hangzhou 1825 Wuhan 1342
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Institute of Hematology & Blood Diseases Hospital, China203 Tianjin Medical University Cancer Institute and Hospital170 Tianjin Medical University Second Hospital28 Tianjin Medical University24 Tianjin Medical University General Hospital19
Site location
Beijing5586 Shanghai3885 Guangzhou3356 Hangzhou1825 Wuhan1342
All 625 locations
Target enrolment
to

Trials with a site in Tianjin

937 of 19224 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Tianjin Medical University Second Hospital
Phase 2
15
Tianjin
2027-08-31
Not yet open
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Phase 3
20
Hangzhou, Tianjin
2027-01-26
Not yet open
Canagliflozin Plus Progestin for Atypical Endometrial Hyperplasia and Early-Stage Endometrial Cancer
NCT07890064Endometrioid Endometrial Cancer, Atypical Endometrial Hyperplasia
DrugsCanagliflozin·Metformin
Wang Yingmei
Phase 2
102
Tianjin
2027-01-01
Not yet open
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Phase 3
90
Tianjin
2026-12-10
Not yet open
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
55
Tianjin
2026-12-01
Not yet open
Keymed Biosciences Co.Ltd
Phase 3
320
Tianjin
2026-12
Not yet open
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 1/2
154
Tianjin
2026-11-30
Not yet open
Sinocelltech Ltd.
Phase 1
12
Tianjin
2026-11-30
Not yet open
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
1,050
Tianjin
2026-11-20
Not yet open
Low-Dose Radiotherapy Plus Adebrelimab and Chemotherapy for Extensive-Stage Small Cell Lung Cancer
NCT07909863Small Cell Lung Cancer (SCLC), SCLC, Extensive Stage
Tianjin Medical University Cancer Institute and Hospital
Phase 2
25
Tianjin
2026-11-15
Not yet open
Supraglottic Oxygenation Via Oral Transtracheal Catheter for Reducing the Incidence of Hypoxemia During ERCP Under Sedation
NCT07637721Choledocholithiasis With Cholecystitis With Obstruction, Obstructive Jaundice, Pancreatitis, Cholelithiasis
Zhejiang University
Not applicable
410
Tianjin, Hangzhou
2026-11-12
Recruiting
Tianjin Eye Hospital
Not applicable
200
Tianjin
2026-11-04
Not yet open
Mazdutide Plus LNG-IUS for Fertility-Sparing Treatment of AEH or Early Endometrial Cancer
NCT07781150Obesity, Overweight, Atypical Endometrial Hyperplasia, Endometrial Carcinoma Stage I
DrugMazdutide
Tongji Hospital
Phase 2
128
Zhengzhou, Wuhan, Changchun, Hangzhou, Shanghai, Tianjin
2026-11-01
Not yet open
Impact of Closed PBSC Collection With Reduced Gas-Phase Oxygen Exposure on Graft Quality and Early Engraftment in Allo-HSCT
NCT07904234Allogeneic Hematopoietic Stem Cell Transplantation (HSCT), Oxygen Deficiency, Graft Function
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
240
Tianjin
2026-11-01
Not yet open
Fecal Microbiota Transplantation Combined With NALIRIFOX Plus Serplulimab as First-line Treatment for Advanced or Metastatic Pancreatic Ductal Adenocarcinoma.
NCT07854977Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
Tianjin Medical University Cancer Institute and Hospital
Phase 2
40
Tianjin
2026-11
Not yet open
Tianjin Medical University Cancer Institute and Hospital
Phase 2
60
Tianjin
2026-11
Not yet open
Study of SGB-9768 in Patients With Paroxysmal Nocturnal Hemoglobinuria
NCT07796256PNH - Paroxysmal Nocturnal Hemoglobinuria
DrugSGB-9768
Suzhou Sanegene Bio Inc.
Phase 2
24
Tianjin, Hangzhou
2026-10-31
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 1
12
Tianjin
2026-10-27
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
15
Tianjin
2026-10-25
Not yet open
Tianjin Medical University Second Hospital
Phase 2
150
Tianjin, Xingtai
2026-10-20
Recruiting
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1
208
Shenyang, Tianjin
2026-10-20
Not yet open
Institute of Hematology & Blood Diseases Hospital, China
Observational
169
Tianjin
2026-10-19
Recruiting
Eli Lilly and Company
Phase 3
1,000
Changchun, Jinan, Luoyang Shi, Nanjing, Ningbo, Shijiazhuang, Tianjin
2026-10-16
Not yet open
Acupuncture for Heel Pain Syndrome
NCT07607223Heel Pain Syndrome
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
Not applicable
150
Tianjin
2026-10-15
Not yet open
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
24
Tianjin
2026-10-15
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Not applicable
30
Tianjin
2026-10-12
Not yet open
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
22
Tianjin
2026-10-12
Not yet open
Nutritional Intervention for Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
NCT07850375Hematopoietic Stem Cell Transplantation (HSCT), Malnutrition (Calorie)
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
160
Changchun, Tianjin, Wenzhou
2026-10-12
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Observational
500
Tianjin
2026-10-12
Not yet open
Tianjin Medical University Cancer Institute and Hospital
Phase 2
20
Tianjin
2026-10-10
Recruiting
Xiaohui Ren
Observational
400
Beijing, Shandong, Tianjin
2026-10-01
Recruiting
Tianjin Medical University Second Hospital
Not applicable
420
Tianjin
2026-10-01
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 1
10
Tianjin
2026-10-01
Not yet open
Fujian Shengdi Pharmaceutical Co., Ltd.
Phase 2
240
Wuhan, Tianjin
2026-10
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 2
30
Tianjin
2026-10
Not yet open
First People's Hospital of Hangzhou
Observational
1,000
Fuzhou, Guangzhou, Jinan, Hangzhou, Beijing, Shanghai, Tianjin
2026-10
Not yet open
Study of Single and Multiple Ascending Doses of CM551 in Healthy Participants
NCT07900945Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis)
Keymed Biosciences Co.Ltd
Phase 1
48
Tianjin
2026-10
Not yet open
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
20
Tianjin
2026-10
Not yet open
Pulsed Field Ablation for Paroxysmal Atrial Fibrillation: Clinical Efficacy and Left Atrial Function Protection
NCT07865221Paroxysmal Atrial Fibrillation, Pulsed Field Ablation, Catheter Ablation, Left Atrial Function
Tianjin Medical University General Hospital
Not applicable
220
Tianjin
2026-10
Not yet open
Tianjin Medical University Cancer Institute and Hospital
Phase 2
80
Tianjin
2026-09-30
Not yet open
Tianjin Medical University Cancer Institute and Hospital
Phase 2
147
Tianjin
2026-09-30
Not yet open
Ruihua Wei
Not applicable
264
Tianjin
2026-09-30
Recruiting
Novartis Pharmaceuticals
Phase 2
259
Beijing, Shanghai, Tianjin
2026-09-29
Not yet open
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
34
Tianjin
2026-09-24
Not yet open
Institute of Hematology & Blood Diseases Hospital, China
Early Phase 1
18
Tianjin
2026-09-20
Not yet open
Tianjin Medical University Cancer Institute and Hospital
Not applicable
150
Tianjin
2026-09-18
Not yet open
Rongchang Pharmaceuticals Co., Ltd.
Phase 1/2
486
Beijing, Hunan, Zhejiang, Shandong, Shanghai, Shanxi, Tianjin
2026-09-15
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
24
Tianjin
2026-09-15
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2
300
Guangzhou, Meizhou, Wuhan, Changsha, Chengdu, Tianjin
2026-09-12
Recruiting
CM336 Plus Isatuximab for Newly Diagnosed Multiple Myeloma With Renal Impairment
NCT07585760Multiple Myeloma (MM), Multiple Myeloma Light Chain Induced Renal Insufficiency
DrugsCM336·Isatuximab
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
26
Tianjin
2026-09-10
Recruiting
Chinese PLA General Hospital
Phase 1
9
Beijing, Tianjin
2026-09-03
Recruiting
Efficacy and Safety of Stereotactic Body Radiation Therapy for Spinal Metastases With Bilsky Grade 1c-3
NCT07809672Stereotactic Body Radiation Therapy (SBRT), Spinal Metastases
Tianjin Medical University Cancer Institute and Hospital
Not applicable
50
Tianjin
2026-09-03
Not yet open
Sphere-9 PAF China Study
NCT07789925Paroxysmal Atrial Fibrillation (PAF)
Medtronic Cardiac Ablation Solutions
Not applicable
180
Beijing, Chengdu, Guangzhou, Hangzhou, Nanjing, Shanghai, Shenyang, Tianjin
2026-09-02
Not yet open
Tianjin Medical University General Hospital
Phase 2
140
Tianjin
2026-09-01
Recruiting
Glycoprotein IIb/IIIa PET/CT in Various GPIIb/IIIa-Related Disease
NCT07813559Thrombi, Thrombus, Brain, Thrombus
Tianjin Medical University
Observational
500
Hefei, Qingdao, Tianjin
2026-09-01
Not yet open
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
20
Tianjin
2026-09-01
Recruiting
Phase II Study of SHR-A1811 for Ultra-Low HER2 Advanced Breast Cancer
NCT07817082Advanced Breast Cancer With Ultra-Low HER2 Expression
DrugTrastuzumab Rezetecan
Tianjin Medical University Cancer Institute and Hospital
Phase 2
30
Tianjin
2026-09-01
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 2
20
Tianjin
2026-09-01
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Not applicable
50
Tianjin
2026-09-01
Not yet open
China Academy of Chinese Medical Sciences
Observational
200
Jinan, Tianjin
2026-09
Not yet open
Yiqi Fumai Lyophilized Injection for Chronic Heart Failure Caused by Coronary Heart Disease
NCT07803471Chronic Heart Failure, Heart Failure With Reduced Ejection Fraction (HFrEF), Coronary Heart Disease (CHD)
DrugYiqi Fumai
China Academy of Chinese Medical Sciences
Not applicable
100
Guangzhou, Zhengzhou, Jinan, Tianjin
2026-09
Not yet open
The First Affiliated Hospital of Zhengzhou University
Observational
500
Guangzhou, Zhengzhou, Shanghai, Chengdu, Tianjin, Kunming
2026-09
Not yet open
Daridorexant for Sleep Disturbance in Adults With Liver Cirrhosis
NCT07830303Liver Cirrhosis, Sleep Disturbance, Hepatic Encephalopathy
DrugDaridorexant
Wang Fengmei
Phase 4
180
Tianjin
2026-09
Not yet open
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1/2
92
Tianjin
2026-09
Not yet open
Tianjin Medical University Cancer Institute and Hospital
Phase 2
50
Tianjin
2026-09
Not yet open
Tianjin Medical University Cancer Institute and Hospital
Phase 2
39
Tianjin
2026-09
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 1
32
Tianjin
2026-08-30
Not yet open
Baduanjin for Quality of Life in Pancreatic Cancer Chemotherapy
NCT07791550Pancreatic Neoplasms, Pancreatic Cancer, Drug-Related Side Effects and Adverse Reactions (MeSH Term)
Tianjin Medical University Cancer Institute and Hospital
Not applicable
96
Tianjin
2026-08-28
Not yet open
Five-Element Music Therapy for Psychological Distress in Pancreatic Cancer Chemotherapy
NCT07796906Pancreatic Neoplasms, Pancreatic Cancer, Anxiety, Depression and/or Anxiety Symptoms
Tianjin Medical University Cancer Institute and Hospital
Not applicable
320
Tianjin
2026-08-28
Recruiting
Eli Lilly and Company
Phase 3
2,001
Chengdu, Hefei, Jinan, Luoyang Shi, Nanjing, Ningbo, Qinhuangdao Shi, Tianjin
2026-08-26
Not yet open
Tianjin Medical University General Hospital
Not applicable
100
Tianjin
2026-08-15
By invitation
A Clinical Study of HY035 Cell Injection in the Treatment of CD7-positive Relapsed or Refractory Hematologic Malignancies
NCT07784309Acute T Cell Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory, Acute Myeloid Leukemia (AML), T Cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 1
13
Tianjin
2026-08-15
Recruiting
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 1
42
Beijing, Xinxiang, Nanjing, Nanchang, Changchun, Jinan, Taiyuan, Tianjin
2026-08-15
Recruiting
Evaluation of Clinical Efficacy and Mechanism of Hand Jing-Well Acupoint Transcutaneous Electrical Stimulation in Improving Post-Stroke Cognitive Impairment
NCT07736885Post-Stroke Cognitive Impairment (PSCI), Ischemic Stroke, Cognitive Dysfunction, Cognitive Disorder, Hemorrhagic Strokes
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
Not applicable
70
Tianjin
2026-08-15
Recruiting
Eli Lilly and Company
Phase 3
1,000
Beijing, Chaohu, Jinan, Linfen, Shanghai, Suzhou, Tianjin, Wenzhou
2026-08-14
Recruiting
Tianjin Medical University Second Hospital
Not applicable
670
Daqing, Nanchang, Tianjin
2026-08-10
Recruiting
Fujian Shengdi Pharmaceutical Co., Ltd.
Phase 2
260
Shanghai, Tianjin
2026-08-06
Recruiting
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
Not applicable
216
Tianjin
2026-08-01
Not yet open
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2
50
Tianjin
2026-08-01
Not yet open
Tianjin Medical University Second Hospital
Phase 2/3
114
Tianjin
2026-08-01
Not yet open
Tianjin Medical University Cancer Institute and Hospital
Phase 1/2
33
Tianjin
2026-08-01
Not yet open
Tianjin Medical University Cancer Institute and Hospital
Phase 2
56
Baotou, Tongliao, Taiyuan, Tianjin
2026-08-01
Recruiting
Tianjin Medical University Second Hospital
Phase 2
32
Tianjin
2026-08-01
Not yet open
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
50
Tianjin
2026-08-01
Not yet open
EEG-Guided Cognitive Function Preservation in Patients With Brain Tumors
NCT07699172Glioma, Brain Neoplasm, Brain Tumor Adult
Bo Wang
Not applicable
10
Tianjin
2026-08-01
Not yet open
Effectiveness of Xuanfei Jiangzhuo Decoction for Influenza-Induced AECOPD
NCT07393685Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Influenza, Human, Virus Diseases
DrugBaloxavir Marboxil
Tianjin Medical University
Observational
300
Tianjin
2026-08-01
Recruiting
AI-assisted Rare Disease Diagnosis
NCT07650799Rare Disorders, Rare Diseases
Peking Union Medical College Hospital
Not applicable
1,056
Cangzhou, Dongguan, Foshan, Guiyang, Jilin City, Kunming, Tianjin, Tianshui
2026-08-01
Not yet open
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
20
Tianjin
2026-08
Recruiting
NK Cells Plus ICI for SCLC Maintenance
NCT07759856Small Cell Lung Cancer
Tianjin First Central Hospital
Phase 2
42
Tianjin
2026-08
Not yet open
Tianjin Medical University Cancer Institute and Hospital
Phase 2
28
Tianjin
2026-08
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 2
120
Beijing, Zhengzhou, Shenyang, Taiyuan, Chengdu, Tianjin
2026-07-31
Not yet open
Tianjin Medical University Cancer Institute and Hospital
Not applicable
46
Tianjin
2026-07-31
Recruiting
Janssen Research & Development, LLC
Phase 2
68
Beijing, Cheng Du Shi, Chengdu, Guangzhou, Jinan, Shanghai, Tianjin
2026-07-28
Recruiting
Alexion Pharmaceuticals, Inc.
Phase 3
20
Beijing, Changchun, Fuzhou, Jinan, Shanghai, Shijiazhuang, Taiyuan, Tianjin
2026-07-27
Not yet open
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
20
Tianjin
2026-07-20
Not yet open
Institute of Hematology & Blood Diseases Hospital, China
Phase 1
30
Tianjin
2026-07-20
Recruiting
A Study of HLX18 vs. OPDIVO® in Multiple Resected Solid Tumors
NCT07518043Esophageal and/or Cardia Cancer, Melanoma, Urothelial Carcinoma (UC)
DrugOpdivo
Shanghai Henlius Biotech
Phase 1
174
Fuzhou, Hangzhou, Luoyang, Tianjin, Wenzhou, Wuhan, Xi'an
2026-07-15
Recruiting
A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies
NCT07609862Mantle Cell Lymphoma (MCL), Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma ( FL), Waldenström Macroglobulinemia (WM)
DrugsLacutoclax·Rocbrutinib
Guangzhou Lupeng Pharmaceutical Company LTD.
Phase 1/2
92
Tianjin
2026-07-14
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 2
49
Tianjin
2026-07-14
Not yet open
Tianjin Medical University Cancer Institute and Hospital
Phase 2
110
Tianjin
2026-07-14
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 4
30
Tianjin
2026-07-14
Not yet open
Plasma ctDNA Monitoring in Pediatric Acute Leukemia
NCT07751588Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Observational
25
Tianjin
2026-07-11
Not yet open
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
40
Tianjin
2026-07-10
Not yet open
Ceftazidime-Avibactam PK/PD and Resistance in Hematology Patients
NCT07703644Hematologic Neoplasms, Gram-Negative Bacterial Infections, Pseudomonas Aeruginosa Infection, Klebsiella Pneumoniae Infections
DrugCeftazidime-avibactam
Sizhou Feng
Observational
60
Tianjin
2026-07-09
Not yet open
A Randomized Controlled Trial of Prophylactic Rituximab to Reduce Clinically Significant EBV DNAemia After Allogeneic Hematopoietic Stem Cell Transplantation
NCT07703657Allogeneic Hematopoietic Stem Cell Transplantation, Epstein-Barr Virus Reactivation, Clinically Significant EBV DNAemia
DrugRituximab
Yang Donglin
Not applicable
168
Tianjin
2026-07-09
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
20
Tianjin
2026-07-07
Recruiting
Juventas Cell Therapy Ltd.
Phase 1
9
Tianjin
2026-07-02
Recruiting
Temporal Interference Stimulation Treatment in Patients With Cognitive Impairment
NCT07643363Amnestic Mild Cognitive Impairment - aMCI, AD-MCI, AD - Alzheimer's Disease, FTD
Tianjin Huanhu Hospital
Not applicable
60
Tianjin
2026-07-01
Not yet open
BeBetter Med Inc
Phase 2
120
Guangzhou, Xi’an, Tianjin
2026-07-01
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 2
52
Tianjin
2026-07-01
Not yet open
Phase II Trial of SFRT Plus Chemo-immunotherapy for LA-NSCLC With Suboptimal Neoadjuvant Response
NCT07670715Locally Advanced Non-small Cell Lung Cancer (NSCLC), Thoracic Radiotherapy, Immune Checkpoint Inhibitors, Neoadjuvant Chemoimmunotherapy
Tianjin Medical University Cancer Institute and Hospital
Phase 2
30
Tianjin
2026-07-01
Not yet open
Shanghai RAAS Blood Products Co., Ltd.
Phase 2
12
Tianjin
2026-07
Not yet open
Tianjin Medical University Cancer Institute and Hospital
Not applicable
96
Tianjin
2026-07
Not yet open
Shandong Suncadia Medicine Co., Ltd.
Phase 3
3,690
Tianjin, Hangzhou
2026-07
By invitation
Compassionate Administration of ZVS101e for Extended Treatment
NCT07307469Bietti Crystalline Corneoretinal Dystrophy
DrugZVS101e
Chigenovo Co., Ltd
Not applicable
32
Beijing, Guangzhou, Zhengzhou, Chengdu, Tianjin
2026-07
Not yet open
SYH2095 for Advanced Malignant Tumors: Phase I Study
NCT07692776Advanced Malignant Tumors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Observational
140
Tianjin
2026-07
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2
32
Tianjin
2026-06-30
Not yet open
Serplulimab Plus Decitabine and CAPOX Before Surgery for Locally Advanced Colorectal Cancer
NCT07691632Locally Advanced Colorectal Cancer, Colorectal Adenocarcinoma
DrugsDecitabine·Serplulimab·Capecitabine
Tianjin Medical University Cancer Institute and Hospital
Phase 2
35
Tianjin
2026-06-30
Active, closed
Boehringer Ingelheim
Phase 2
344
Huzhou, Jinan, Luoyang, Nanjing, Ningbo, Qinhuangdao, Tianjin, Yichang
2026-06-30
Not yet open
Tianjin Medical University Cancer Institute and Hospital
Phase 2
120
Tianjin
2026-06-30
Recruiting
Monoamine Oxidase A PET/CT in Various MAO-A-Related Disease
NCT07685860Depression, Anxiety, Heart Injuries
Tianjin Medical University
Observational
200
Hefei, Qingdao, Tianjin
2026-06-25
Recruiting
Monoamine Oxidase B PET/CT in Various MAO-B-Related Disease
NCT07685873Parkinson Disease, Parkinson Disease Dementia, Parkinson's Disease and Parkinsonism
Tianjin Medical University
Observational
200
Hefei, Qingdao, Tianjin
2026-06-25
Recruiting
Hoffmann-La Roche
Phase 3
380
Guangzhou, Nanjing, Qingdao, Tianjin, Kunming, Hangzhou, Jinan, Nanning
2026-06-23
Recruiting
Tianjin First Central Hospital
Phase 2
50
Tianjin
2026-06-23
Recruiting
BeOne Medicines
Phase 1
118
Lanzhou, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Suzhou, Nanchang, Tianjin
2026-06-23
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 4
38
Tianjin
2026-06-22
Recruiting
Tianjin First Central Hospital
Not applicable
132
Tianjin
2026-06-16
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 2
56
Tianjin
2026-06-15
Active, closed
Hangzhou Gensciences Biopharmaceutical Co., Ltd.
Phase 3
60
Tianjin, Fuyang, Fuzhou, Guangzhou, Hefei, Jinan, Kunming, Nanning
2026-06-12
Recruiting
A Study of Automated Axicabtagene Ciloleucel for R/R Large B-cell Lymphoma.
NCT07606937Relapsed/Refractory Large B-cell Lymphoma
Shenzhen Fosun Kairos Biotechnology Co., Ltd.
Early Phase 1
12
Beijing, Guangzhou, Suzhou, Shanghai, Chengdu, Tianjin
2026-06-12
Active, closed
Eparlitozoviril as Adjuvant Therapy for Resectable HCC With MVI
NCT07658105HCC - Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2
60
Tianjin
2026-06-12
Active, closed
Induction Chemoimmunotherapy Followed by Deescalated Definitive Radiotherapy in Head and Neck Cancer
NCT07791602Head and Neck Squamous Cell Carcinoma, Locally Advanced Head and Neck Cancer, HNSCC
DrugsTuoyi·Camrelizumab
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
180
Beijing, Harbin, Shenyang, Taiyuan, Tianjin
2026-06-12
Not yet open
Exploratory Study of SHR-A1811 Via Different Administration Routes in Patients
NCT07560475HER2positive, Advanced Breast Cancer, HER2 + Breast Cancer
DrugTrastuzumab Rezetecan
Tianjin Medical University Cancer Institute and Hospital
Phase 2
60
Tianjin
2026-06-10
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 3
198
Tianjin
2026-06-09
Not yet open
Yi Shuhua
Phase 2
60
Shenzhen, Zhengzhou, Changsha, Nanjing, Nanchang, Jinan, Tianjin
2026-06-08
Recruiting
Shandong Suncadia Medicine Co., Ltd.
Phase 2
92
Nanjing, Tianjin
2026-06-04
Recruiting
Jiangsu HengRui Medicine Co., Ltd.
Phase 1
190
Tianjin
2026-06-03
Recruiting
Phase I Study of FXS0683 in the Treatment of Blood Tumors
NCT07616089B-Cell Lymphoma, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Acute Lymphoblastic Leukemia
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Phase 1
228
Tianjin
2026-06-02
Not yet open
Tianjin Medical University Cancer Institute and Hospital
Phase 2
26
Tianjin
2026-06-01
Recruiting
Programmed Cell Death Ligand 1 PET/CT in Various PD-L1-Related Disease Patients
NCT07618936PD-L1 Gene Mutation, PD-L1 Gene Amplification, PD-L1-related Disease, Positron Emission Tomography
Tianjin Medical University
Observational
500
Hefei, Qingdao, Tianjin
2026-06-01
Not yet open
A Long-term Efficacy and Safety of NTQ5082 Capsules
NCT07177872Paroxysmal Nocturnal Hemoglobinuria
DrugNTQ5082
Nanjing Chia-tai Tianqing Pharmaceutical
Phase 3
78
Tianjin
2026-06
Not yet open
A Trial of HRS-7058 in Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment
NCT07601048KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment
DrugsGarsorasib·Fulzerasib·HRS-7058
Shandong Suncadia Medicine Co., Ltd.
Phase 3
450
Tianjin
2026-06
Recruiting
Tianjin Medical University Second Hospital
Phase 2
120
Tianjin, Xingtai
2026-05-30
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
92
Tianjin
2026-05-30
Not yet open
Sonazoid CEUS for Early HCC Surveillance
NCT07590284Liver Cirrhosis, Liver Fibrosis
Tianjin Third Central Hospital
Not applicable
556
Tianjin
2026-05-30
Recruiting
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1/2
178
Beijing, Harbin, Tianjin
2026-05-27
Recruiting
Yanbing Yu
Not applicable
142
Beijing, Nanning, Shijiazhuang, Nanjing, Nantong, Nanchang, Shanghai, Tianjin
2026-05-23
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 3
288
Tianjin
2026-05-22
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Not applicable
60
Tianjin
2026-05-20
Recruiting
Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of EVER001 in Participants With Selected Proteinuric Glomerular Diseases
NCT07614477Minimal Change Disease (MCD), IgA Nephropathy (IgAN), Focal Segmental Glomerulosclerosis (FSGS)
Everest Medicines (China) Co.,Ltd.
Phase 2
45
Beijing, Tianjin
2026-05-20
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Not applicable
60
Tianjin
2026-05-20
Recruiting
R-PMDT Regimen in Newly Diagnosed PCNSL
NCT07604987Primary Central Nervous System (CNS) Lymphoma
Zou Dehui
Phase 2
33
Tianjin
2026-05-20
Recruiting
SIM0613 in Participants With Advanced Solid Tumors
NCT07618260Advanced Solid Cancer
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1
294
Tianjin
2026-05-15
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 3
788
Tianjin
2026-05-15
Not yet open
Tianjin Medical University General Hospital
Not applicable
200
Tianjin
2026-05-15
Active, closed
First Hospital of China Medical University
Not applicable
6,800
Cangzhou, Suzhou, Panjin, Shenyang, Jinzhou, Tianjin
2026-05-14
Recruiting
Ipsen
Phase 3
350
Beijing, Guangzhou, Zhengzhou, Nanchang, Changchun, Jinan, Shanghai, Tianjin
2026-05-14
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
22
Tianjin
2026-05-13
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Observational
50
Tianjin
2026-05-10
Recruiting
Efficacy of Liposomal Bupivacaine for Transversus Abdominis Plane Block
NCT07577934Postoperative Pain, Liposomal Bupivacaine
Tianjin First Central Hospital
Not applicable
86
Tianjin
2026-05-10
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
27
Tianjin
2026-05-08
Recruiting
Novo Nordisk A/S
Phase 3
300
Beijing, Guangzhou, Shenzhen, Luoyang, Nanjing, Tianjin
2026-05-05
Not yet open
Tianjin Medical University General Hospital
Not applicable
160
Tianjin
2026-05-05
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 2
130
Tianjin
2026-05-01
Recruiting
Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure
NCT07528274NSCLC (Non-small Cell Lung Cancer), NSCLC (Advanced Non-small Cell Lung Cancer)
DrugsTislelizumab·Docetaxel
Tianjin Medical University Cancer Institute and Hospital
Phase 2
20
Tianjin
2026-05-01
Recruiting
SNRK & Vascular Endothelial Aging
NCT07591337Vascular Aging
Tianjin Medical University
Observational
180
Tianjin
2026-05-01
Not yet open
A Phase II Study of Benmelstobart + Anlotinib + Chemotherapy as First-Line Treatment for LCNEC and EP-NEC
NCT07510594Large-Cell Neuroendocrine Carcinoma of the Lung, Extrapulmonary Neuroendocrine Carcinoma
DrugsBenmelstobart·Anlotinib·Etoposide
Tianjin Medical University Cancer Institute and Hospital
Phase 2
48
Tianjin
2026-05-01
Not yet open
SmartNuclide Biopharma
Early Phase 1
20
Tianjin
2026-05-01
Recruiting
HELP Therapeutics Co., Ltd.
Phase 3
80
Tianjin
2026-04-30
Recruiting
Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
NCT07354074Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, Philadelphia Chromosome Positive
DrugsAsciminib single agent·ABL001
Novartis Pharmaceuticals
Phase 2
50
Zhengzhou, Tianjin
2026-04-28
Recruiting
Hoffmann-La Roche
Phase 3
360
Beijing, Fuzhou, Guangzhou, Chengdu, Tianjin
2026-04-27
Active, closed
Tianjin Medical University Cancer Institute and Hospital
Phase 2
107
Tianjin
2026-04-24
Not yet open
Institute of Hematology & Blood Diseases Hospital, China
Early Phase 1
24
Tianjin
2026-04-15
Not yet open
Chengdu Syncor Pharmaceutical Co., Ltd.
Phase 2
80
Tianjin
2026-04-15
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1
156
Tianjin
2026-04-15
Not yet open
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
27
Shenzhen, Zhengzhou, Nanchang, Jinan, Tianjin
2026-04-15
Not yet open
Safety and Efficacy of DIT101 in Relapsed or Refractory Hematologic Malignancies
NCT07485504Relapsed or Refractory Hematologic Malignancies
Tcelltech Inc.
Phase 1
15
Tianjin
2026-04-15
Recruiting
Eli Lilly and Company
Phase 2
65
Beijing, Shanghai, Tianjin
2026-04-14
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 2
40
Tianjin
2026-04-14
Active, closed
Hangzhou Gensciences Biopharmaceutical Co., Ltd.
Phase 3
60
Tianjin, Fuyang, Fuzhou, Ganzhou, Guangzhou, Hefei, Huai'an, Jinan
2026-04-14
Recruiting
Nanjing Leads Biolabs Co.,Ltd
Phase 2
110
Beijing, Shijiazhuang, Jinan, Qingdao, Taiyuan, Tianjin
2026-04-13
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
110
Tianjin
2026-04-10
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
80
Tianjin
2026-04-10
Recruiting
HPB-092 for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia
NCT07137637Relapsed and Refractory Acute Myeloid Leukemia (RR-AML)
Hangzhou Polymed Biopharmaceuticals, Inc.
Phase 1
60
Tianjin
2026-04-10
Recruiting
Lepu Biopharma Co., Ltd.
Phase 1/2
160
Beijing, Fuzhou, Zhengzhou, Nanjing, Tianjin, Lishui
2026-04-08
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
43
Tianjin
2026-04-08
Recruiting
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2
100
Chengdu, Tianjin
2026-04-08
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 2
114
Tianjin
2026-04-08
Recruiting
ImmVira Pharma Co. Ltd
Phase 1/2
36
Tianjin
2026-04-03
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2/3
216
Tianjin
2026-04-02
Not yet open
Tianjin Medical University Cancer Institute and Hospital
Phase 2
93
Tianjin
2026-04-01
Not yet open
Hepatopancreatobiliary Surgery Institute of Gansu Province
Not applicable
100
Lanzhou, Xi'an, Tianjin
2026-04-01
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Not applicable
60
Tianjin
2026-04-01
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Observational
100
Tianjin
2026-04-01
Not yet open
yilong Wang
Not applicable
86
Beijing, Kaifeng, Xinxiang, Zhengzhou, Linyi, Tianjin
2026-04-01
Not yet open
Tianjin Medical University Cancer Institute and Hospital
Phase 2
28
Tianjin
2026-04-01
Recruiting
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
Not applicable
200
Wuhan, Tianjin, Xining
2026-04-01
Not yet open
Tianjin Medical University General Hospital
Phase 3
752
Tianjin
2026-04
Not yet open
Tianjin Medical University
Phase 4
300
Tianjin
2026-04
Not yet open
Effect of Acupuncture on Psychoneurological Symptom Cluster in Breast Cancer Survivors
NCT07481903Psychoneurological Symptom Cluster(Pain, Insomnia, Anxiety, Fatigue, Depression, Subjective Cognitive Decline), Pain, Insomnia, Anxiety
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
Not applicable
228
Beijing, Nanjing, Qingdao, Tianjin
2026-04
Not yet open
Electroacupuncture for the Prevention of Recurrent Lower Urinary Tract Infection in Women
NCT07507851Urinary Tract Infections, Recurrent, Electroacupuncture, Randomized Controlled Trial (RCT)
Yanjun Zhang, Baoyan Liu
Not applicable
312
Beijing, Tianjin
2026-04
Not yet open
Institute of Hematology & Blood Diseases Hospital, China
Phase 1
9
Tianjin
2026-04
Recruiting
Acupuncture for Post-Stroke Dysphagia: A Clinical Study
NCT07493902Post-stroke Dysphagia, Acupuncture
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
Not applicable
3,232
Tianjin
2026-04
Recruiting
Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid Tumors
NCT07589205Solid Tumor, Colorectal Cancer, Non-small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
Phase 1
493
Tianjin
2026-03-31
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Not applicable
264
Tianjin
2026-03-30
Recruiting
BioNTech SE
Phase 1/2
533
Chongqing, Guangzhou, Hangzhou, Shanghai, Tianjin
2026-03-30
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 2
43
Tianjin
2026-03-30
Recruiting
Bristol-Myers Squibb
Phase 1/2
474
Beijing, Guangzhou, Tianjin, Harbin, Changsha Shi, Nanjing, Shanghai Shi
2026-03-26
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 3
340
Tianjin
2026-03-23
Recruiting
A Phase II Trial of G01 Eye Drops for Glaucomatous Optic Neuropathy
NCT07777861Primary Open-Angle Glaucoma, Optic Nerve Injury
Qingdao WanMing BioCell Pharmaceutics Co.,Ltd.
Phase 2
90
Beijing, Guangzhou, Shantou, Changsha, Tianjin, Hangzhou, Wenzhou
2026-03-18
Recruiting
Chengdu Zenitar Biomedical Technology Co., Ltd
Phase 2
64
Chengdu, Tianjin
2026-03-18
Recruiting
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 1
15
Beijing, Suzhou, Jinan, Tianjin, Hangzhou
2026-03-17
Recruiting
Tianjin Medical University Second Hospital
Phase 2
53
Tianjin, Xingtai
2026-03-16
Recruiting
Jie Li
Not applicable
80
Tianjin
2026-03-16
Recruiting
Suzhou Alphamab Co., Ltd.
Phase 3
70
Tianjin
2026-03-13
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 2
46
Tianjin
2026-03-12
Recruiting
Pfizer
Phase 1/2
132
Beijing, Nanjing, Tianjin, Ningbo
2026-03-11
Recruiting
Novartis Pharmaceuticals
Phase 2
210
Guangzhou, Wuhan, Beijing, Shanghai, Tianjin
2026-03-09
Recruiting
Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Phase 3
358
Tianjin
2026-03-09
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 3
106
Tianjin
2026-03-03
Not yet open
Institute of Hematology & Blood Diseases Hospital, China
Phase 1
18
Tianjin
2026-03-02
Active, closed
Tianjin Medical University Cancer Institute and Hospital
Observational
300
Tianjin
2026-03-01
Not yet open
Kunming Pharmaceuticals, Inc.
Phase 1
54
Tianjin
2026-03-01
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 2
49
Beijing, Wuhan, Chengdu, Tianjin
2026-03-01
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 4
30
Tianjin
2026-03-01
Recruiting
West China Hospital
Observational
2,000
Hefei, Chongqing, Guangzhou, Harbin, Wuhan, Nanjing, Tianjin
2026-03-01
Not yet open
Tianjin Huanhu Hospital
Early Phase 1
15
Tianjin
2026-03
Recruiting
Using Liquid Biopsy Testing to Identify, Monitor, Predict Recurrence in Urothelial Carcinoma
NCT07441499Urothelial Carcinoma (UC), Bladder (Urothelial, Transitional Cell) Cancer, Liquid Biopsy
Tianjin Medical University Second Hospital
Observational
300
Tianjin
2026-03
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
20
Tianjin
2026-03
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
122
Tianjin
2026-03
Recruiting
Etiology-Phenotype-Outcome Pathway Study on Freezing of Gait (FOG)
NCT07386015Freezing of Gait, Parkinson's Disease, Parkinsonism, Vascular Parkinsonism
Tianjin Huanhu Hospital
Observational
700
Tianjin
2026-02-28
Recruiting
AbbVie
Phase 1
127
Tianjin, Hangzhou
2026-02-27
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2
2
Tianjin
2026-02-25
Active, closed
Tianjin Medical University Cancer Institute and Hospital
Phase 2
30
Tianjin
2026-02-24
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Observational
200
Tianjin
2026-02-23
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Observational
100
Xiamen, Tianjin
2026-02-15
By invitation
Novo Nordisk A/S
Observational
100,000
Tianjin
2026-02-13
Recruiting
Chengdu Zenitar Biomedical Technology Co., Ltd
Phase 3
105
Chengdu, Tianjin
2026-02-13
Recruiting
Eli Lilly and Company
Phase 2
450
Changsha, Chengdu, Hangzhou, Suzhou, Tianjin, Wuhu, Xi'an, Zhumadian
2026-02-10
Recruiting
Andon Health Co., Ltd
Observational
392
Tianjin
2026-02-09
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 2
58
Tianjin
2026-02-03
Not yet open
Tianjin Medical University Cancer Institute and Hospital
Phase 2
29
Tianjin
2026-02-01
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 2
25
Tianjin
2026-02-01
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 2
25
Tianjin
2026-02-01
Recruiting
Tianjin Anding Hospital
Observational
200
Tianjin
2026-01-31
Not yet open
A Study of CD19 UCAR-T Cells in Subjects With Autoimmune Diseases
NCT07212322Systemic Lupus Erythematosus, Idiopahic Inflammatory Myopathies, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Sjögren's Syndrome
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
24
Tianjin
2026-01-30
Recruiting
Genmab
Phase 2
240
Shanghai, Beijing, Changchun, Nanjing, Tianjin, Zhangjiakou, Zhengzhou
2026-01-30
Recruiting
Hope Medicine (Nanjing) Co., Ltd
Phase 3
540
Beijing, Nanning, Suzhu, Shanghai, Tianjin
2026-01-29
Recruiting
Shanxi Kangbao Biological Product Co., Ltd.
Phase 1/2
30
Tianjin
2026-01-29
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
160
Tianjin
2026-01-28
Recruiting
A Single-Arm Phase Ⅱ Study of Fluzoparib Maintenance in Platinum-sensitive Advanced Triple-Negative Breast Cance
NCT07321015Platinum-sensitive, TNBC, Triple Negative Breast Cancer, BRCA1/2 Mutation or Not
DrugFluzoparib
Tianjin Medical University Cancer Institute and Hospital
Phase 2
72
Tianjin
2026-01-20
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
160
Tianjin
2026-01-20
Not yet open
Wangjing Hospital, China Academy of Chinese Medical Sciences
Not applicable
106
Beijing, Changsha, Tianjin
2026-01-15
Recruiting
Effects of PFO Closure on Glymphatic Function and Clinical Symptoms in Patients With Migraine
NCT07170176Migraine Disorders, Patent Foramen Ovale, Right-to-Left Shunt, Cardiac
First Affiliated Hospital Xi'an Jiaotong University
Not applicable
150
Luoyang, Tianjin
2026-01-14
Not yet open
Institute of Hematology & Blood Diseases Hospital, China
Early Phase 1
38
Zhengzhou, Wuhan, Xuzhou, Nanchang, Beijing, Tianjin
2026-01-10
Recruiting
IASO206 in Patients With Relapsed/Refractory Multiple Myeloma
NCT07322159Relapsed/Refractory Multiple Myeloma (RRMM)
Institute of Hematology & Blood Diseases Hospital, China
Early Phase 1
18
Tianjin
2026-01-08
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 2
27
Tianjin
2026-01-06
Recruiting
Tianjin Medical University General Hospital
Phase 4
320
Baoding, Tangshan, Tianjin
2026-01-06
Not yet open
Critical Illness After Hematopoietic Cell Transplantation
NCT07328724Critical Illness, Ventilated Patients, Hematopoetic Stem Cell Transplantation, Transplant Complication
Peking University People's Hospital
Observational
4,000
Beijing, Chongqing, Hangzhou, Harbin, Tianjin, Wuhan
2026-01-01
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Not applicable
150
Tianjin
2026-01-01
Recruiting
CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases
NCT07315087SLE - Systemic Lupus Erythematosus, SSc-Systemic Sclerosis, IIM- Idiopathic Inflammatory Myopathies, ANCA Associated Vasculitis (AAV)
DrugQT-019C
Institute of Hematology & Blood Diseases Hospital, China
Phase 1
12
Tianjin
2026-01-01
Active, closed
Multimodal Prediction of Postoperative Prognosis After Partial Nephrectomy for Endophytic Renal Cell Carcinoma
NCT07697417Renal Cell Carcinoma, Kidney Neoplasms, Endophytic Renal Tumor, Postoperative Renal Function
Tianjin Medical University Second Hospital
Observational
406
Tianjin
2026-01-01
Recruiting
Modified Zipper Therapy for AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder
NCT07420296Neuromyelitis Optica Spectrum Disorders (NMOSD)
Tianjin Medical University General Hospital
Phase 3
198
Tianjin
2026-01-01
Not yet open
Ganzhou Hemay Pharmaceutical Co., Ltd
Phase 2
120
Tianjin
2026-01-01
Recruiting
Hippocampus-Protective Radiotherapy Combined With Osimertinib for Symptomatic Brain Metastases in EGFR-Mutated Lung Cancer
NCT07505173Naive Advanced Non-small Cell Lung Cancer With EGFR-sensitive Mutations (EGFR Exon 19 Deletion and Exon 21 L858R Mutation) and Symptomatic Brain Metastases
Tianjin Medical University Cancer Institute and Hospital
Phase 2
74
Tianjin
2026-01-01
Not yet open
Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety Study
NCT07365410Non-small Cell Lung Cancer (NSCLC), Brain Metastases, Furmonertinib, EGFR Mutation
DrugsFurmonertinib·Pemetrexed·Carboplatin
Tianjin Medical University Cancer Institute and Hospital
Phase 2
60
Tianjin
2026-01
Recruiting
Tianjin Anding Hospital
Observational
300
Tianjin
2025-12-31
Not yet open
Tianjin Medical University Cancer Institute and Hospital
Observational
860
Tianjin
2025-12-31
Recruiting
Bristol-Myers Squibb
Phase 2/3
990
Hefei, Chongqing, Fuzhou, Fuzhou Fujian, Guangzhou, Shenzhen, Nanning, Tianjin
2025-12-31
Not yet open
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
43
Tianjin
2025-12-30
By invitation
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
8
Tianjin
2025-12-29
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
34
Tianjin
2025-12-25
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 2
30
Cangzhou, Tianjin
2025-12-22
Recruiting
Eye & ENT Hospital of Fudan University
Phase 2
116
Harbin, Jinan, Beijing, Shanghai, Tianjin
2025-12-22
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
37
Tianjin
2025-12-20
Recruiting
Janssen Research & Development, LLC
Phase 3
800
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Nanjing, Shanghai, Tianjin
2025-12-19
Recruiting
Grit Biotechnology
Early Phase 1
36
Tianjin
2025-12-18
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Observational
60
Tianjin
2025-12-18
Recruiting
Sinotau Pharmaceutical Group
Phase 2
40
Beijing, Tianjin
2025-12-18
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2
37
Tianjin
2025-12-17
Not yet open
Tianjin Medical University Cancer Institute and Hospital
Phase 2
188
Guangzhou, Shijiazhuang, Luoyang, Nanyang, Chengdu, Tianjin, Jiaxing
2025-12-15
Recruiting
Xian-Janssen Pharmaceutical Ltd.
Observational
200
Beijing, Changzhou, Guangzhou, Hangzhou, Nanjing, Shenzhen, Shijiazhuang, Tianjin
2025-12-11
Recruiting
Danyang Huichuang Medical Equipment Co., Ltd.
Phase 3
320
Beijing, Shijiazhuang, Baotou, Suzhou, Xi'an, Shanghai, Taiyuan, Tianjin
2025-12-10
Active, closed
Tianjin Medical University Cancer Institute and Hospital
Observational
400
Tianjin
2025-12-09
Recruiting
Jiangsu HengRui Medicine Co., Ltd.
Phase 2
218
Nanjing, Tianjin
2025-12-08
Active, closed
Tianjin Medical University Cancer Institute and Hospital
Phase 1
15
Tianjin
2025-12-04
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 2
216
Tianjin
2025-12-03
Recruiting
Bristol-Myers Squibb
Phase 3
650
Beijing, Haidian District, Guangzhou, Shenzhen, Changsha, Nanjing, Tianjin, Hangzhou
2025-12-02
Recruiting
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 1/2
100
Tianjin
2025-12-02
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 2
31
Tianjin
2025-12-01
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 2
41
Tianjin
2025-12-01
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
100
Tianjin
2025-12-01
Not yet open
Tianjin Medical University Cancer Institute and Hospital
Phase 2
31
Tianjin
2025-12
Recruiting
Electroacupuncture Combined With PD-1 Inhibitor for ECOG2 Advanced NSCLC
NCT07239661Non-Small Cell Lung Cancer, Electroacupuncture, PD-1 Inhibitors, ECOG PS 2 Points
Kong Fanming
Not applicable
120
Tianjin
2025-11-30
Not yet open
A Clinical Study to Explore CT1195E in Patients With Relapsed/Refractory B-Cell Neoplasms
NCT07234045Relapsed/Refractory B-cell Non-Hodgkin Lymphoma, Relapsed/Refractory B-cell ALL
Institute of Hematology & Blood Diseases Hospital, China
Phase 1
30
Tianjin
2025-11-30
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2
20
Tianjin
2025-11-29
Recruiting
Chengdu New Radiomedicine Technology Co. LTD.
Phase 1
132
Shanghai, Tianjin
2025-11-29
Recruiting
Keymed Biosciences Co.Ltd
Phase 2
48
Tianjin
2025-11-27
Recruiting
Shanghai RAAS Blood Products Co., Ltd.
Phase 2
24
Changsha, Hefei, Jinan, Nanning, Suzhou, Taiyuan, Tangshan, Tianjin
2025-11-26
Recruiting
Nephron-sparing Treatment of Tislelizumab + Nab-Paclitaxel for Renal Pelvic Cancer
NCT07233252Renal Pelvic Carcinoma, Tislelizumab, PD-1 Inhibitor, Kidney-sparing
DrugsNab-paclitaxel·Tislelizumab
Tianjin Medical University Second Hospital
Phase 2
35
Tianjin
2025-11-25
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Not applicable
80
Tianjin
2025-11-24
Recruiting
Eli Lilly and Company
Phase 2
400
Changsha, Hangzhou, Huzhou, Jinan, Shanghai, Shijiazhuang, Tianjin, Xiamen
2025-11-24
Not yet open
Zhang Jianguo
Not applicable
86
Beijing, Wuhan, Nanjing, Dalian, Jinan, Shanghai, Tianjin, Hangzhou
2025-11-24
Recruiting
A Study of CM336 in Patients With Relapsed or Refractory Autoimmune Cytopenia
NCT07175493Autoimmune Cytopenia, Immune Thrombocytopenia (ITP), Autoimmune Hemolytic Anemia, Evans Syndrome
DrugCM336
Keymed Biosciences Co.Ltd
Phase 1/2
158
Zhengzhou, Changzhi, Tianjin
2025-11-18
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
400
Changchun, Tianjin, Hangzhou
2025-11-15
Recruiting
Sinotau Pharmaceutical Group
Phase 3
395
Beijing, Foshan, Tianjin
2025-11-14
Recruiting
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 3
464
Fuzhou, Harbin, Nanjing, Jinan, Tianjin, Hangzhou
2025-11-12
Recruiting
AstraZeneca
Phase 1/2
83
Guangzhou, Tianjin
2025-11-12
Recruiting
Qilu Pharmaceutical Co., Ltd.
Phase 3
228
Tianjin
2025-11-07
Recruiting
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1
232
Beijing, Nanjing, Shanghai, Tianjin, Wuhan
2025-11-07
Recruiting
Qilu Pharmaceutical Co., Ltd.
Phase 1/2
212
Tianjin
2025-11-05
Recruiting
Shanghai Synvida Biotechnology Co.,Ltd.
Phase 2
48
Chengdu, Guangzhou, Hangzhou, Nanchang, Nanjing, Neimeng, Shanghai, Tianjin
2025-11-04
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 2
120
Tianjin
2025-11-03
Recruiting
[18F]NIDF PET Imaging in Tau-related Diseases
NCT07306598Neurodegenerative Disease, Alzheimer s Disease, Tauopathies
Tianjin Medical University
Observational
20
Hefei, Qingdao, Tianjin
2025-11-01
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 2
30
Tianjin
2025-11-01
Not yet open
Peking University First Hospital
Not applicable
1,508
Beijing, Tianjin
2025-11
Not yet open
Nanjing Chia-tai Tianqing Pharmaceutical
Phase 3
78
Tianjin
2025-11
Not yet open
Tianjin Medical University Cancer Institute and Hospital
Phase 2
165
Tianjin
2025-11
Recruiting
Eli Lilly and Company
Phase 3
1,205
Beijing, Chengdu, Guangzhou, Harbin, Luoyang Shi, Nanjing, Shanghai, Tianjin
2025-10-31
Recruiting
Pfizer
Phase 2
200
Beijing, Guangzhou, Shijiazhuang, Shanghai, Tianjin, Hangzhou
2025-10-30
Not yet open
Institute of Hematology & Blood Diseases Hospital, China
Phase 1
20
Tianjin
2025-10-30
Active, closed
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
1,096
Nanchang, Shenyang, Hangzhou, Tianjin
2025-10-24
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Not applicable
60
Tianjin
2025-10-20
Recruiting
Wayshine Biopharm, Inc.
Phase 1/2
48
Fuzhou, Tianjin, Shanghai
2025-10-17
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2
23
Tianjin
2025-10-17
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 1
15
Tianjin
2025-10-16
Recruiting
A Study of HRS-2329 in Participants With Advanced Solid Tumors Harboring RAS Mutations or Amplifications
NCT07189949Advanced Solid Tumors Harboring RAS Mutations or Amplifications
DrugHRS-2329
Jiangsu HengRui Medicine Co., Ltd.
Phase 1
120
Tianjin
2025-10-16
Recruiting
Tao Liu
Not applicable
143
Beijing, Tianjin
2025-10-15
Recruiting
Bristol-Myers Squibb
Phase 1
32
Beijing, Fuzhou, Guangzhou, Shenzhen, Harbin, Xinxiang, Jinan, Tianjin
2025-10-15
Recruiting
Takeda
Phase 3
20
Beijing, Guangzhou, Jihan, Shanghai, Suzhou, Tianjin, Wuhan
2025-10-13
Recruiting
Brain Cognitive Network Abnormalities in Anemia Patients Using fNIRS
NCT07578675Aplastic Anemia, Myelodysplastic Syndromes, Autoimmune Hemolytic Anemia, Functional Near-Infrared Spectroscopy
Institute of Hematology & Blood Diseases Hospital, China
Observational
323
Tianjin
2025-10-11
Recruiting
Genentech, Inc.
Phase 1/2
285
Jinan, Shanghai, Tianjin, Fuzhou, Nanning
2025-10-07
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 2
100
Tianjin
2025-10-01
Recruiting
Tianjin Medical University Second Hospital
Not applicable
144
Tianjin
2025-10-01
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Early Phase 1
15
Tianjin
2025-10-01
Recruiting
SmartNuclide Biopharma
Early Phase 1
12
Tianjin
2025-10-01
Not yet open
Tianjin Medical University Cancer Institute and Hospital
Phase 2
45
Fuzhou, Shijiazhuang, Harbin, Jinan, Tianjin
2025-10
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Observational
38
Tianjin
2025-09-30
Not yet open
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 3
546
Jinan, Tianjin
2025-09-30
Recruiting
Hoffmann-La Roche
Observational
300
Langfang, Tianjin, Beijing, Changchun, Chengdu, Guangzhou, Harbin, Jinan
2025-09-29
Recruiting
Guiding Value of Urinary Tumor DNA Testing in Repeat Transurethral Resection of Non-Muscle-Invasive Bladder Cancer
NCT07187635Bladder Cancer, Liquid Biopsy, Repeat Transurethral Resection of Bladder Tumor
Tianjin Medical University Second Hospital
Not applicable
350
Nanchang, Guangzhou, Xingtai, Kunming, Shanghai, Tianjin
2025-09-28
Recruiting
A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia
NCT07205315B-cell Acute Lymphoblastic Leukemia (B-ALL), Chronic Lymphocytic Leukemia (CLL), B-cell Non-Hodgkin's Lymphoma (B-NHL), Autoimmune Hemolytic Anemia (AIHA)
DrugGT801
Grit Biotechnology
Early Phase 1
28
Zhengzhou, Tianjin
2025-09-26
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 2
30
Tianjin
2025-09-25
Not yet open
Institute of Hematology & Blood Diseases Hospital, China
Observational
17
Tianjin
2025-09-25
Recruiting
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2
150
Shanghai, Tianjin
2025-09-23
Recruiting
Chengdu Zenitar Biomedical Technology Co., Ltd
Phase 2
60
Tianjin
2025-09-23
Recruiting
Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC)
NCT07179783Prostate Cancer (Adenocarcinoma), Prostate Cancer Metastatic Castration-Resistant, Prostate Adenocarcinoma With Neuroendocrine Differentiation
DrugsTagitanlimab·Sacituzumab tirumotecan
Tianjin Medical University Second Hospital
Phase 2
28
Tianjin
2025-09-22
Recruiting
Ruihua Wei
Not applicable
180
Tianjin
2025-09-20
Not yet open
Tianjin Medical University Cancer Institute and Hospital
Observational
300
Tianjin
2025-09-20
Active, closed
Tianjin Medical University Second Hospital
Not applicable
360
Xingtai, Guangzhou, Haerbin, Kunming, Nanchang, Tianjin
2025-09-20
By invitation
Ruihua Wei
Not applicable
60
Tianjin
2025-09-20
Recruiting
Akeso
Phase 2
160
Shanghai, Tianjin
2025-09-19
Recruiting
LCAR-F33S in Treatment of Relapsed/Refractory Multiple Myeloma
NCT07100067Relapsed/Refractory Multiple Myeloma(MM)
Nanjing Legend Biotech Co.
Not applicable
35
Beijing, Tianjin, Wuhan
2025-09-16
Not yet open
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
10
Tianjin
2025-09-15
Recruiting
Tao Liu
Not applicable
30
Tianjin
2025-09-15
Recruiting
Qilu Pharmaceutical Co., Ltd.
Phase 2
160
Tianjin
2025-09-12
Recruiting
Janssen Research & Development, LLC
Phase 3
220
Beijing, Chengdu, Guangzhou, Nanjing, Ningbo, Tianjin, Wenzhou, Wuhan
2025-09-10
Not yet open
Tianjin Medical University Cancer Institute and Hospital
Phase 2
35
Tianjin
2025-09-10
By invitation
Tianjin Medical University Cancer Institute and Hospital
Not applicable
50
Tianjin
2025-09-10
Active, closed
Tianjin Medical University General Hospital
Phase 2
110
Tianjin
2025-09-09
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 2
52
Tianjin
2025-09-08
Recruiting
A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)
NCT07139873Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
DrugsIdelalisib·Birelentinib·Bendamustine·Rituximab
Dizal Pharmaceuticals
Phase 3
250
Nanjing, Tianjin
2025-09-08
Recruiting
Maxinovel Pty., Ltd.
Phase 2
43
Tianjin
2025-09-05
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
47
Tianjin
2025-09-04
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
21
Tianjin
2025-09-04
Recruiting
CD5 CART for the Treatment of Relapsed and Refractory CD5 Hematological Tumors
NCT07234110Relapsed and Refractory CD5 Hematological Tumors
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
18
Tianjin
2025-09-03
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 1
3
Tianjin
2025-09-01
Recruiting
Tianjin Medical University Second Hospital
Observational
60
Tianjin
2025-09-01
Not yet open
Tianjin Medical University Cancer Institute and Hospital
Phase 2
47
Tianjin
2025-09-01
Recruiting
Tianjin Medical University Second Hospital
Not applicable
150
Tianjin
2025-09-01
Recruiting
Tianjin Medical University Second Hospital
Not applicable
220
Tianjin
2025-09-01
Recruiting
Post-transplantation Maintenance Therapy With Cidabenamide in Patients With Intermediate/High-risk AML
NCT07304232Allogeneic Hematopoietic Cell Transplantation (HCT), AML (Acute Myeloid Leukemia)
DrugChidamide
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
134
Shijiazhuang, Harbin, Tianjin
2025-09-01
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 4
31
Tianjin
2025-09-01
Not yet open
Keymed Biosciences Co.Ltd
Phase 3
280
Tianjin
2025-09
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 3
228
Tianjin
2025-08-31
Recruiting
Beijing Biostar Pharmaceuticals Co., Ltd.
Phase 2/3
778
Anyang, Guangzhou, Jinan, Shenyang, Taiyuan, Tianjin, Wuhan, Zhengzhou
2025-08-28
Recruiting
Haisco Pharmaceutical Group Co., Ltd.
Phase 1
110
Tianjin
2025-08-28
Recruiting
Radiation Combined With BCMA/CD3 Bispecific Antibody Therapy for Solitary Bone Plasmacytoma With Mild Bone Marrow Infiltration
NCT07115667Solitary Bone Plasmacytoma, Plasmacytoma of Bone, Plasma Cell Disorders
DrugCM336
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
21
Tianjin
2025-08-25
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 2
29
Tianjin
2025-08-22
Not yet open
Tianjin Central Hospital of Gynecology Obstetrics
Not applicable
604
Tianjin
2025-08-20
Recruiting
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
NCT07005154Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer, Metastatic Hormone Sensitive Prostate Cancer
DrugsPRL-02·Abiraterone acetate·Prednisolone·Prednisone
Astellas Pharma Global Development, Inc.
Phase 2
218
Yangzhou, Tianjin, Hangzhou, Huaian, Shanghai
2025-08-19
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Observational
400
Tianjin
2025-08-18
Recruiting
Sanofi
Phase 3
90
Beijing, Chengde, Guangzhou, Hohhot, Nanchang, Suzhou, Tianjin, Wuhan
2025-08-18
Recruiting
Wayshine Biopharm, Inc.
Phase 2
40
Fuzhou, Wuhan, Shanghai, Tianjin
2025-08-18
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
30
Tianjin
2025-08-15
By invitation
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Not applicable
26
Tianjin
2025-08-15
Not yet open
Tianjin Medical University Cancer Institute and Hospital
Phase 1/2
59
Tianjin
2025-08-15
Recruiting
Akeso
Phase 3
760
Beijing, Fuzhou, Shijiazhuang, Harbin, Shanghai, Tianjin
2025-08-14
Not yet open
Prognostic Model for MASLD Related Cirrhosis
NCT07082751Metabolic Dysfunction Associated Steatotic Liver Disease, Compensated Cirrhosis
Beijing Friendship Hospital
Observational
228
Beijing, Tianjin
2025-08-13
Recruiting
A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases
NCT07123519Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN), Sjogren's Syndrome (SS), Inflammatory Myopathy
DrugYTS109 cell
China Immunotech (Beijing) Biotechnology Co., Ltd.
Phase 1
18
Tianjin
2025-08-13
Recruiting
BioNTech SE
Phase 1/2
1,438
Chongqing, Hangzhou, Tianjin, Wuhan
2025-08-12
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
60
Tianjin
2025-08-12
Recruiting
A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma
NCT07106671CRS - Cytokine Release Syndrome, Myeloma
DrugSiltuximab
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
20
Tianjin
2025-08-10
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
20
Tianjin
2025-08-09
Active, closed
AstraZeneca
Phase 3
212
Beijing, Changsha, Chengdu, Chongqing, Nanjing, Shanghai, Tianjin, Wuhan
2025-08-07
Active, closed
Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers
NCT07162181Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, B-cell Lymphoma
DrugPirtobrutinib
Eli Lilly and Company
Phase 2
13
Beijing, Guangzhou, Harbin, Shanghai, Tianjin, Wuhan
2025-08-07
Recruiting
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
NCT07114601Breast Neoplasms, Colorectal Neoplasms, Prostate Neoplasm, Endometrial Neoplasms
Eli Lilly and Company
Phase 1
421
Beijing, Tianjin
2025-08-06
Recruiting
BCMA/CD3 BsAb Therapy for POEMS Syndrome
NCT07115654POEMS Syndrome
DrugCM336
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
10
Tianjin
2025-08-04
Not yet open
Liu Hongfang
Not applicable
228
Beijing, Guangzhou, Changchun, Tianjin
2025-08-01
Recruiting
SightGlass Vision, Inc.
Not applicable
175
Changsha, Chengdu, Guangzhou, Shanghai, Tianjin
2025-08-01
Not yet open
Liu Hongfang
Observational
4,472
Beijing, Guangzhou, Changchun, Tianjin
2025-08-01
Not yet open
RN1201 Injection in Newly Diagnosed High-Risk Cytogenetic Multiple Myeloma
NCT07114432Newly Diagnosed High-Risk Cytogenetic Multiple Myeloma Patients Ineligible or Unwilling to Undergo ASCT, Newly Diagnosed Multiple Myeloma (NDMM)
DrugBCMA/CD19-targeted allogeneic CAR-T
Tianjin Medical University Cancer Institute and Hospital
Phase 1
19
Tianjin
2025-08
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
30
Tianjin
2025-08
Recruiting
Romiplostim N01 for Chemotherapy-induced Thrombocytopenia
NCT07063225Chemotherapy-induced Thrombocytopenia, Romiplostim N01
DrugIpilimumab
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
50
Tianjin
2025-08
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
20
Tianjin
2025-08
Recruiting
Tianjin Medical University Second Hospital
Phase 2
40
Tianjin
2025-07-31
Recruiting
Eli Lilly and Company
Phase 1/2
68
Guangzhou, Jinan, Tianjin, Wuhan
2025-07-30
Recruiting
Keymed Biosciences Co.Ltd
Phase 2
90
Beijing, Tianjin
2025-07-25
Recruiting
Tasly Biopharmaceuticals Co., Ltd.
Phase 1
32
Beijing, Guangzhou, Datong, Tianjin, Wenzhou
2025-07-24
Recruiting
[18F]FT8 PET Imaging in Immunoglobulin Light Chain Amyloidosis
NCT07232459Amyloid, Cardiac Amyloidosis, Amyloidosis, Healthy Subjects
Tianjin Medical University
Observational
25
Hefei, Qingdao, Tianjin
2025-07-21
Not yet open
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
11
Tianjin
2025-07-20
Recruiting
Bristol-Myers Squibb
Phase 3
450
Beijing, Guangzhou, Baoding, Changsha, Nanjing, Xi'an, Chengdu, Tianjin
2025-07-18
Not yet open
Institute of Hematology & Blood Diseases Hospital, China
Phase 1
27
Tianjin
2025-07-15
Recruiting
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2
48
Tianjin
2025-07-10
Recruiting
Electroacupuncture Combined With PD-1 Inhibitor for Elderly Patients With Advanced NSCLC
NCT07086300Elderly Patients (>65 Years), Non-Small Cell Lung Cancer, PD-1 Inhibitors, Electroacupuncture
Kong Fanming
Not applicable
120
Tianjin
2025-07-08
Recruiting
Neoadjuvant Tislelizumab in Combination With Nab-Paclitaxel for UTUC
NCT07126119Upper Tract Urothelial Carcinoma, Neoadjuvant Therapy, PD-1 Inhibitor, Nab-paclitaxel
DrugsNab-paclitaxel·Tislelizumab
Tianjin Medical University Second Hospital
Phase 2
35
Tianjin
2025-07-05
Recruiting
Neoadjuvant Tislelizumab + Nab-Paclitaxel Followed by Distal Ureterectomy for Ureteral Cancer
NCT07125547Ureteral Cancer, Neoadjuvant Therapy, PD-1 Inhibitor, Kidney-sparing
DrugsPD-1 inhibitior·Nab-paclitaxel
Tianjin Medical University Second Hospital
Phase 2
35
Tianjin
2025-07-05
By invitation
Tianjin Medical University Cancer Institute and Hospital
Not applicable
300
Tianjin
2025-07-05
Recruiting
Shandong New Time Pharmaceutical Co., LTD
Phase 2
90
Tianjin
2025-07-02
Recruiting
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1
630
Beijing, Guangzhou, Harbin, Nanchang, Shenyang, Jinan, Shanghai, Tianjin
2025-07-02
Recruiting
Spatially Fractionated Radiotherapy Combined With Immunotherapy for Advanced Solid Tumors
NCT07058948Solid Cancers, Radiotherapy, Immune Checkpoint Inhibitor, Lung Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2
30
Beijing, Cangzhou, Tianjin
2025-07-01
Not yet open
Tianjin Medical University Cancer Institute and Hospital
Phase 2
37
Fuzhou, Shijiazhuang, Changsha, Jinan, Qingdao, Tianjin
2025-07
Not yet open
Tianjin Medical University Cancer Institute and Hospital
Phase 2
46
Tianjin
2025-06-30
Recruiting
SupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies
NCT07153068T Lymphoblastic Leukemia/Lymphoma, Acute Myeloid Leukemia (AML)
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2
12
Tianjin
2025-06-28
Recruiting
uCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies
NCT07109518Acute Myeloid Leukemia (AML), T Lymphoblastic Leukemia/Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 1
12
Tianjin
2025-06-28
Recruiting
CD180 CART for Relapsed or Refractory CD180 Positive Hematologic Malignancies
NCT07106749Acute Myeloid Leukemia, B Acute Lymphoblastic Leukemia/Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 1
12
Tianjin
2025-06-28
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 1
18
Tianjin
2025-06-28
Recruiting
Avizor SA
Not applicable
152
Beijing, Tianjin
2025-06-27
Recruiting
A Study of CT0596 in Plasma Cell Leukemia
NCT06988059Plasma Cell Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Early Phase 1
27
Tianjin
2025-06-25
Active, closed
Incyte Corporation
Phase 1/2
32
Beijing, Chengdu, Chongoing, Guangzhou, Hangzhou, Shanghai, Tianjin, Wuhan
2025-06-25
Recruiting
Entinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab Failure
NCT07708194Breast Cancer, HER2-positive Breast Cancer, Hormone Receptor-Positive Breast Cancer, Metastatic Breast Cancer
DrugsEntinostat·Pyrotinib
Tianjin Medical University Cancer Institute and Hospital
Phase 1/2
94
Tianjin
2025-06-23
Not yet open
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
134
Tianjin
2025-06-20
Recruiting
BeBetter Med Inc
Phase 1
90
Tianjin
2025-06-17
Recruiting
Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/B Cell Maturation Antigen （CD19/BCMA） in Patients With r/r Neurological Autoimmune Diseases
NCT06939166Neuromyelitis Optica Spectrum Disorders, Myasthenia Gravis, Multiple Sclerosis, Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Tianjin Huanhu Hospital
Early Phase 1
12
Tianjin
2025-06-17
Recruiting
QL1706-Based Therapy Post-PD-1/L1 Failure in Advanced Endometrial Cancer
NCT06917092Endometrial Adenocarcinoma, Endometrial Cancer
DrugLenvatinib
Tianjin Medical University Cancer Institute and Hospital
Phase 2
30
Tianjin
2025-06-16
Recruiting
Bristol-Myers Squibb
Phase 3
274
Beijing, Wuhan, Changsha, Jining Shi, Tianjin
2025-06-13
Not yet open
Optimal Timing of Hepatitis B Vaccination After Transplants
NCT06888479Transplant-Related Disorder, Hepatitis B Virus Infection, Vaccine Reaction
DrugHepatitis B vaccine
Institute of Hematology & Blood Diseases Hospital, China
Phase 3
1,500
Tianjin
2025-06-01
Recruiting
Postoperative Edge (RapidArc) Stereotactic Body Radiotherapy for Spinal Metastases
NCT07801274Spinal Metastases, Metastatic Epidural Spinal Cord Compression, Spinal Cord Compression
Tianjin Medical University Cancer Institute and Hospital
Observational
50
Tianjin
2025-06-01
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
50
Tianjin
2025-06-01
Recruiting
Real-world Studies of CDK4/6 Inhibitors
NCT07407439Breast Cancer
Tianjin Medical University Cancer Institute and Hospital
Observational
245
Tianjin
2025-06-01
Not yet open
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
60
Tianjin
2025-05-30
Not yet open
Tianjin Medical University Cancer Institute and Hospital
Phase 2
30
Tianjin
2025-05-25
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 1
37
Tianjin
2025-05-22
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
129
Tianjin
2025-05-22
Recruiting
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2
80
Tianjin
2025-05-22
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Observational
36
Tianjin
2025-05-19
Recruiting
Alexion Pharmaceuticals, Inc.
Phase 3
450
Guangzhou, Hangzhou, Hengyang, Nanning, Shenzhen, Taiyuan, Tianjin, Zhengzhou
2025-05-19
Recruiting
Yunhe Pharmaceutical (Tianjin) Co., Ltd
Phase 1/2
55
Wuxi, Tianjin
2025-05-14
Active, closed
Hoffmann-La Roche
Phase 1
20
Guangzhou, Tianjin, Nanchang, Wenzhou, Wuhan
2025-05-13
Recruiting
Jiangsu BioJeTay Biotechnology Co., Ltd.
Phase 1/2
56
Bengbu, Beijing, Tangshan, Zhengzhou, Nanchang, Xi’an, Tianjin
2025-05-12
Recruiting
Phase I Study of BC008-1A Injection in Patients With Advanced Solid Tumors
NCT06773507Advanced Esophageal Cancers, Advanced Non-small Cell Lung Cancer (NSCLC)
DrugBC008-1A
Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd.
Phase 1
80
Tianjin
2025-05-12
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
25
Tianjin
2025-05-09
Recruiting
S-INFINITY Pharmaceuticals Co., Ltd
Phase 2
24
Tianjin
2025-04-30
Recruiting
Shandong Suncadia Medicine Co., Ltd.
Phase 2
300
Beijing, Tianjin
2025-04-28
Not yet open
Selinexor Combined With Azacitidine Therapy in High-Risk Myeloid Neoplasms Patients
NCT06900088Acute Myeloid Leukemia, Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia
DrugSelinexor
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
20
Tianjin
2025-04-25
Recruiting
Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Phase 2
30
Tianjin
2025-04-24
Recruiting
Grit Biotechnology
Phase 1/2
46
Tianjin
2025-04-18
Recruiting
Cullgen (Shanghai),Inc
Phase 1
45
Nanchang, Tianjin, Wuhan
2025-04-17
Recruiting
Nanjing IASO Biotechnology Co., Ltd.
Phase 1
70
Nanjing, Tianjin
2025-04-11
Recruiting
Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases
NCT07022197Chronic Inflammatory Demyelinating Polyradiculoneuropathy, NMO Spectrum Disorder, Myasthenia Gravis, Idiopathic Inflammatory Myopathies
Tianjin Medical University General Hospital
Phase 1/2
27
Tianjin
2025-04-10
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
20
Beijing, Tianjin
2025-04-09
Recruiting
Peking University Cancer Hospital & Institute
Phase 1/2
42
Neimeng, Baoding, Baotou, Beijing, Dalian, Tianjin
2025-04-08
Recruiting
Evaluation of SYS6005 in Patients With Advanced Malignant Tumor
NCT06958679B-cell Malignancies, Solid Tumors
CSPC Megalith Biopharmaceutical Co.,Ltd.
Phase 1
132
Tianjin
2025-04-03
Recruiting
Alpha-Synuclein PET/CT in Various α-Syn-Related Disease
NCT06949670Alpha Synuclein Pathology, Alpha-Synuclein, Parkinson Disease
Tianjin Medical University
Observational
500
Hefei, Qingdao, Tianjin
2025-04-01
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 2
38
Tianjin
2025-04-01
Recruiting
A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies
NCT06914037Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma (CTCL), NHL (Non-Hodgkin Lymphoma)
DrugCHT101
Tianjin Medical University Cancer Institute and Hospital
Phase 1
24
Tianjin
2025-03-31
Recruiting
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 4
430
Tianjin
2025-03-29
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Early Phase 1
9
Tianjin
2025-03-28
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 2
30
Tianjin
2025-03-28
Recruiting
Jianmin Pharmaceutical Group Co., LTD.
Phase 2
216
Harbin, Changsha, Changchun, Jinan, Luzhou, Tianjin, Wenzhou
2025-03-26
By invitation
Cohort of Cord Blood Bank
NCT07249099Health Status, Childhood Diseases
Institute of Hematology & Blood Diseases Hospital, China
Observational
2,000
Tianjin
2025-03-25
Recruiting
Keymed Biosciences Co.Ltd
Phase 1/2
110
Tianjin
2025-03-25
Recruiting
Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma
NCT06830031Diffuse Large B-cell-lymphoma, DLBCL, Nos Genetic Subtypes, Follicular Lymphoma Grade 3B, PMBL
Shanghai Exuma Biotechnology Ltd.
Phase 1
18
Tianjin
2025-03-25
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Observational
60
Dalian, Harbin, Shenyang, Tianjin
2025-03-25
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 1
15
Tianjin
2025-03-18
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
40
Tianjin
2025-03-18
Recruiting
RenJi Hospital
Observational
114
Beijing, Guangdong, Guizhou, Jiangsu, Shanghai, Sichuan, Tianjin, Zhejiang
2025-03-13
Recruiting
Tianjin Medical University General Hospital
Not applicable
75
Fuzhou, Tianjin
2025-03-11
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 2
33
Tianjin
2025-03-07
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2
50
Tianjin
2025-03-03
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
174
Tianjin
2025-03-03
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
80
Tianjin
2025-03-03
Recruiting
Autologous Transplantation Combined With BCMA CAR-T in the Treatment of UHR-MM
NCT07109323Ultra High Risk mm (uhr-mm), 18-70 Years Old, Suitable for ASCT. And Meet Any of the Following uhr-mm Definitions, Cytogenetics Ultra High Risk, Primary Refractory, Early Progression
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2
50
Tianjin
2025-03-03
Recruiting
Reproductive and Mental Health of Patients With Aplastic Anemia
NCT06936930Aplastic Anemia, Reproductive Health
Institute of Hematology & Blood Diseases Hospital, China
Observational
600
Tianjin
2025-03-03
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
20
Tianjin
2025-03-03
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 3
394
Tianjin
2025-03-01
Active, closed
Combination of Remimazolam and Propofol During Drug-induced Sleep Endoscopy
NCT06784479Sedative Effect During Drug-induced Sleep Endoscopy, Obstructive Sleep Apnea (OSA)
DrugPropofol
Dan Liu
Phase 4
174
Tianjin
2025-03-01
Not yet open
Keymed Biosciences Co.Ltd
Phase 1/2
125
Tianjin
2025-03
Recruiting
Second-line Immunotherapy for ES-SCLC
NCT06853678Extensive Stage Small Cell Lung Cancer (ES-SCLC)
DrugsSelinexor·Adebrelimab·Nab-paclitaxel
Tianjin Medical University Cancer Institute and Hospital
Not applicable
30
Tianjin
2025-02-28
Recruiting
Glofitamab Combination With Chidamide in Patients With Recurrent/Refractory DLBCL
NCT06570447Diffuse Large B-Cell Lymphoma-Recurrent, Diffuse Large B-Cell Lymphoma-Refractory
DrugsGlofitamab·Chidamide
Tianjin Medical University Cancer Institute and Hospital
Phase 2
22
Tianjin
2025-02-27
Active, closed
A Study of YTS109 Cell Injection in Subjects With Relapsed/Refractory Autoimmune Hemolytic Anemia
NCT06770504Autoimmune Hemolytic Anemia, Anti-CD19 STAR T-cell Therapy, Failure ≥3 Lines of Therapies
Institute of Hematology & Blood Diseases Hospital, China
Phase 1
7
Tianjin
2025-02-26
Active, closed
Amgen
Phase 2
252
Beijing, Fuzhou, Guangzhou, Harbin, Changsha, Taiyuan, Chengdu, Tianjin
2025-02-26
Recruiting
Brain Function and Psychological Changes Related to Cell Therapy for Autoimmune Hemolytic Anemia
NCT06921980CAR T-cell Therapy, Autoimmune Hemolytic Anemia, Brain Function, Psychological Well-Being
Institute of Hematology & Blood Diseases Hospital, China
Observational
20
Tianjin
2025-02-25
Recruiting
Tianjin Eye Hospital
Not applicable
100
Tianjin
2025-02-18
Recruiting
Hangzhou Reprogenix Bioscience, Inc
Phase 1
10
Tianjin
2025-02-17
Recruiting
Chinese PLA General Hospital
Phase 1/2
30
Beijing, Changzhi, Tianjin
2025-02-15
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 1
15
Tianjin
2025-02-14
Recruiting
CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases
NCT06941129Systemic Lupus Erythematosus, Systemic Sclerosis (SSc), Inflammatory Myopathy, ANCA-Associated Vasculitis (AAV)
Institute of Hematology & Blood Diseases Hospital, China
Phase 1
12
Tianjin
2025-02-11
Active, closed
AbbVie
Phase 3
468
Beijing, Guangzhou, Shijiazhuang, Wuhan, Suzhou, Xi'an, Taiyuan, Tianjin
2025-02-10
Not yet open
Clinical Classification of MAFLD Based Liver Biopsy
NCT06795646Metabolic Dysfunction Associated Steatotic Liver Disease, Metabolic Dysfunction-associated Steatohepatitis (MASH)
Beijing Friendship Hospital
Observational
2,000
Beijing, Hangzhou, Shanghai, Tianjin
2025-02-08
Rows per page Showing 1–500 of 937
1 2 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 11 November 2026. https://priyalifescience.com/clinical-trials-china/city/tianjin

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,224 studies in total at the last sync on 11 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 937 of those studies with a site in Tianjin.

How many clinical trials are recruiting in Tianjin?

594 of the 937 studies on this page are recruiting new participants as of the 11 Nov 2026, 03:17 UTC sync. A further 159 have not yet opened recruitment, 158 are active but closed to new participants, and 26 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Tianjin), 937 studies
PhaseStudiesRecruitingShare
Phase 229219031.2%
Not applicable1478315.7%
Phase 31175612.5%
Observational1147712.2%
Phase 11137712.1%
Phase 1/21047611.1%
Early Phase 123182.5%
Phase 416111.7%
Phase 2/31161.2%

Most active sponsors

Lead sponsors with the most studies (Tianjin)
Lead sponsorStudiesRecruiting
Institute of Hematology & Blood Diseases Hospital, China203140
Tianjin Medical University Cancer Institute and Hospital170103
Tianjin Medical University Second Hospital2822
Tianjin Medical University2421
Tianjin Medical University General Hospital199
Hoffmann-La Roche134
Eli Lilly and Company1210
Novartis Pharmaceuticals123
Jiangsu HengRui Medicine Co., Ltd.118
Tianjin Huanhu Hospital119
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.